Kyle Gano reports an option exercise and tax withholding on shares
By AlphaYouPublished Form 4
Gano Kyle
Reporting filer
Kyle Gano reports an option exercise and tax withholding on shares, not an open-market purchase or sale, in Neurocrine Biosciences Inc. Form 4 filed Nov 3, 2026 lists 3 entries.
- Disclosed
- Nov 3, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Gano Kyle | 2026-11-01 | M | Exercise or conversion | 614 | 0 | 155,342 | 2 days | Filed terms
|
| Common Stock | Gano Kyle | 2026-11-01 | F | Tax/exercise withholding | 332 | 146.10 | 155,010 | 2 days | Filed terms
|
| Restricted Stock Unit (derivative) | Gano Kyle | 2026-11-01 | M | Exercise or conversion | 614 | 0 | 1,228 | 2 days | Filed terms
|
Common Stock
- Owner
- Gano Kyle
- Date
- 2026-11-01
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 614
- Price
- 0
- Following holdings
- 155,342
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-01
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 614
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 155342
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Gano Kyle
- Date
- 2026-11-01
- Code
- F
- Action
- Tax/exercise withholding
- Quantity
- 332
- Price
- 146.10
- Following holdings
- 155,010
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-01
- transaction Form Type: 4
- transaction Code: F
- equity Swap Involved: 0
- transaction Shares: 332
- id: F1
- transaction Price Per Share: 146.10
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 155010
- direct Or Indirect Ownership: D
Restricted Stock Unit (derivative)
- Owner
- Gano Kyle
- Date
- 2026-11-01
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 614
- Price
- 0
- Following holdings
- 1,228
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Restricted Stock Unit
- id: F2
- transaction Date: 2026-11-01
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 614
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F3
- id: F3
- underlying Security Title: Common Stock
- underlying Security Shares: 614
- shares Owned Following Transaction: 1228
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Gano Kyle: Chief Executive Officer, Director.
- F1: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3: This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.
Original sources
Prepared automatically from public filing data. Report a correction.